Cipla has signed a strategic agreement with the Indian National Association for the Study of Liver (INASL) to intensify India’s battle against hepatitis‑B and‑C. The deal includes co‑development of advanced rapid blood‑test kits, nationwide awareness drives and free liver‑health camps.

Hepatitis remains a major public‑health challenge in India, with an estimated 45 million people living with the virus. Government initiatives over the past five years have reduced infection rates, yet the 2030 elimination target demands accelerated action.

The core objective of Cipla’s initiative is to expand testing access in rural and underserved regions. Partnering with INASL scientists, Cipla has engineered a next‑generation quick‑test that delivers results in under 15 minutes, slated for integration into the national health program.

Historical Background

India’s fight against hepatitis began in the 1990s with the launch of the first national strategy. The 2005 Hepatitis Control Programme emphasized vaccination and blood safety. In 2022, WHO endorsed India’s commitment to eliminate hepatitis‑C, prompting renewed public‑private collaborations.

Why This Matters

BozokMedia analysis shows that collaborations between private pharma and government research bodies can dramatically accelerate disease control. This alliance not only boosts testing volumes but also shortens the time to treatment, reducing long‑term complications.

"The Cipla‑INASL partnership marks a decisive step toward a hepatitis‑free India," says Dr. Anita Gupta, public‑health expert.

Frequently Asked Questions

Q1: Who will benefit most from this partnership?
A: Residents of rural areas, urban slums and low‑income groups are the primary beneficiaries.

Q2: How accurate are the new test kits?
A: The rapid test boasts 98 % sensitivity and 99 % specificity.